Floatz logo

Inotersen

Pregnancy Disorder

Akcea Therapeuticsnucleic_acidUnknownActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Pregnancy Disorder cohort.

Asset / SponsorPhaseRating
Cefazolin
MemorialCare Health System
Phase 4BBB
Metformin
Norwegian University of Science and Technology
Phase 4BBB
ROPIVACAINE
Northwestern University
Phase 4BB
Folic Acid
University Magna Graecia
Phase 4BB
CLOMIPHENE CITRATE
Yale University
Phase 3BB

View all 23 →

Same molecule, other indications

Inotersen is also rated in:

familial amyloid neuropathyActive
BB
Indicative · Phase 4
70 / 100
View asset →
amyloidosisDormant
BB
Indicative · Phase 3
64 / 100
View asset →
hereditary amyloidosisDormant
D
Indicative · Unknown
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →